J Korean Med Sci.
2019 Oct;34(41):e277. 10.3346/jkms.2019.34.e277.
What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
- Affiliations
-
- 1Department of Medicine, Seoul National University College of Medicine, Seoul, Korea. kimjinw@snu.ac.kr
- 2Department of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- KMID: 2460926
- DOI: http://doi.org/10.3346/jkms.2019.34.e277
Abstract
- No abstract available.
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment of Chronic Hepatitis C Patients Who Do Not Respond to Direct Acting Antivirals
- Hepatitis C Virus and Antiviral Drug Resistance
- 2017 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis C: What's New?
- Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
- Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
